Other equities analysts have also issued research reports about the stock. ValuEngine upgraded shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 4th. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, April 1st. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. Finally, Mizuho reiterated a “buy” rating and set a $62.00 target price on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $43.33.
ATRA traded down $1.22 during trading on Thursday, hitting $26.00. 1,321,645 shares of the company’s stock were exchanged, compared to its average volume of 718,757. Atara Biotherapeutics has a fifty-two week low of $25.83 and a fifty-two week high of $54.45. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -4.93 and a beta of 2.11.
In other Atara Biotherapeutics news, SVP Derrell Porter sold 5,909 shares of the stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $40.00, for a total transaction of $236,360.00. Following the transaction, the senior vice president now directly owns 27,597 shares in the company, valued at $1,103,880. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christopher Haqq sold 13,975 shares of the stock in a transaction that occurred on Monday, February 11th. The shares were sold at an average price of $38.55, for a total transaction of $538,736.25. Following the transaction, the executive vice president now owns 272,718 shares in the company, valued at $10,513,278.90. The disclosure for this sale can be found here. Insiders sold 150,649 shares of company stock worth $5,594,893 over the last ninety days. 10.60% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. Manchester Capital Management LLC bought a new position in shares of Atara Biotherapeutics in the first quarter worth approximately $56,000. Quantamental Technologies LLC bought a new position in shares of Atara Biotherapeutics in the fourth quarter worth approximately $62,000. Tower Research Capital LLC TRC bought a new position in shares of Atara Biotherapeutics in the third quarter worth approximately $103,000. SG Americas Securities LLC bought a new stake in Atara Biotherapeutics in the third quarter valued at $108,000. Finally, Meeder Asset Management Inc. bought a new stake in Atara Biotherapeutics in the fourth quarter valued at $128,000.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.